Midi Health: menopause telehealth unicorn after the FDA removed the 22-year boxed warning

Virtual clinic for perimenopause and menopause care — hormone and non-hormone treatment covered by insurance — expanding into an AI-enabled platform for women's midlife health.

That menopause was an unserved mass market that telehealth plus specialist clinicians could serve — if regulation stopped scaring women off hormone therapy.

$250M total funding. $100M Series D led by Goodwater Capital with Serena Ventures (Feb 2026); earlier $60M Series B led by Emerson Collective with Google Ventures participating.

Joanna Strober hit perimenopause insomnia around 47 and had to drive 45 minutes out of San Francisco and pay $750 out of pocket just to get a diagnosis. The failure was mass-market, not personal. Pandemic-era changes to US telehealth rules made a virtual clinic possible — Strober says Midi couldn't have existed without them — and she launched Midi in 2021 to connect midlife women with clinicians actually trained in menopause.

Midi kept raising while digital health funding collapsed: a $60M Series B led by Emerson Collective with Google Ventures participating, in a year when the category's funding fell nearly in half. Then the demand headwind lifted. On November 10, 2025 the FDA announced it would strip the boxed warning — installed after the 2002 Women's Health Initiative findings, carried by more than 20 hormone products — from menopause hormone therapy, a change FDA Commissioner Marty Makary had championed and obstetricians said had scared patients off prescriptions for two decades.

In February 2026 Midi closed a $100M Series D at a valuation past $1 billion, becoming the first menopause-care unicorn, and is expanding into a broader AI-enabled platform for women across life stages.

The market failure was regulatory in origin: after the 2002 Women's Health Initiative fallout, a boxed warning chilled hormone prescriptions for 22 years.

Telehealth rules were the first opening: without pandemic-era flexibility, Strober says, Midi could not have existed at all.

Specialization beat generalists: clinicians trained in midlife women's health solved a routing problem primary care never did.

Insurance, not cash-pay, was the scale lever: coverage reaching 45 million-plus women turned a niche clinic into a national platform.

Regulation can be a demand ceiling, not just a license: for two decades a warning label shrank an entire market. Founders who build ahead of the ceiling collect the rebound when the rule lifts.

As of early 2026 Midi is spending its $100M Series D becoming the platform layer for women's midlife health: senior hires including a new CFO, CMO and chief commercial officer, a proprietary AI engine for charting and triage, and company-reported outcomes such as higher cancer-screening adherence and lower total cost of care versus matched groups. The FDA label change is now the category's tailwind, and rivals from hormone telehealth startups to retail clinics are chasing the same newly unlocked demand.